Report of Foreign Issuer (6-k)
December 13 2018 - 6:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of:
December 2018
Commission
file number:
001- 38041
THERAPIX
BIOSCIENCES LTD.
(Translation
of registrant’s name into English)
4
Ariel Sharon Street
HaShahar
Tower, 16th Floor
Givatayim
5320047, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
INFORMATION
CONTAINED IN THIS FORM 6-K REPORT
On
December 13, 2018, Therapix Biosciences Ltd. (the “
Company
”) issued a press release providing an update to
shareholders regarding the previously announced binding letter of intent dated October 22, 2018 between the Company and FSD Pharma
Inc. The press release is attached as Exhibit 99.1 to this report.
The
information contained in this Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement
on Form F-3 (File No. 333-225745) and Registration Statement on Form S-8 (File No. 333-225773).
Forward
Looking Statements:
Matters
discussed in this Report on Form 6-K contain forward-looking statements within the meaning of the “safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future
events and are based on the Company’s current expectations, they are subject to various risks and uncertainties and actual
results, performance or achievements of the Company could differ materially from those described in or implied by the statements
in this report. For example, forward-looking statements in this report include statements regarding the proposed FSD Pharma Inc.
transaction. The forward-looking statements contained or implied in this report are subject to other risks and uncertainties,
including those discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission (“
SEC
”) on April 30, 2018 and in subsequent filings with the
SEC. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances
or otherwise.
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Therapix
Biosciences Ltd.
|
|
|
|
|
By
|
/s/
Ascher Shmulewitz
|
|
Name:
|
Ascher
Shmulewitz, M.D, Ph.D.
|
|
Title:
|
Chief
Executive Officer
|
Date:
December 13, 2018
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2023 to Apr 2024